Proliferation, ploidy and prognosis in uterine smooth muscle tumours

Histopathology

Volumn 29, Issue 3, 1996, Pages 217-223

  Jeffers, M D ^a,b   Oakes, S J ^a   Richmond, J A ^a   Macaulay, E M ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Ki 67; Leiomyosarcoma; Mitoses; Ploidy; Proliferation; Uterus

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MITOSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029744658     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.1996.tb01394.x     Document Type: Article

References (30)

1. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. Am. J. Surg. Pathol. 1994: 18; 535-558.
2. Hall PA, Levison DA. Review: Assessment of cell proliferation in histological material. J. Clin. Pathol. 1990: 43; 184-142.
3. Baak JPA. Mitosis counting in tumours. Hum. Pathol. 1990: 21; 683-685.
4. Going JJ. Efficiently estimated histologic cell counts. Hum. Pathol. 1994: 25; 333-336.
5. Keshyegian AA, Cnaan A. Proliferation markers in breast carcinoma. Am. J. Clin. Pathol. 1995: 104; 42-49.
6. Lloveras B, Garin-Chesa P, Mye A, Melamed M. In vitro bromodeoxyuridine labeling of malignant neoplasms. Am. J. Clin. Pathol. 1944: 101; 703-707.
7. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumours. Cancer 1990: 65; 1194-1205.
8. Hall PA, Levison DA, Woods AL. Proliferating cell nuclear antigen (PCNA) immunolocalisation in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 1990: 162; 285-294.
9. Robbins BA, Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch. Pathol. Lab. Med. 1987: 111; 841-845.
10. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma vs. bizarre and cellular leiomyomas of the uterus: A comparative study based on the Ki67 and proliferating cell nuclear antigen indices, p53 expression. DNA flow cytometry and muscle specific actins. Int. J. Gyn. Path. 1995: 14; 134-142.
11. Kempson RL, Hendrickson MR. Pure mesenchymal neoplasms of the uterine corpus. In Fox H ed. Obstetrical and Gynaecological Pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1987: 428-429.
12. Prayson RA, Hart WR. Milotically active leiomyoma of the uterus. Am. J. Clin. Pathol. 1992: 97; 14-20.
13. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br. J. Obstet. Gynaecol. 1992: 99; 590-594.
14. Silverberg SG. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumours of the uterus. Hum. Pathol. 1976: 7; 451-454.
15. Major FJ, Blessing JA. Silverberg SG et al. Prognostic factors in early stage uterine sarcoma. Cancer 1993: 71; 1702-1709.
16. Peters WA, Howard DR, Andersen WA, Figge DC. Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Am. J. Obstet. Gynecol. 1992: 166; 1646-1654.
17. Ellis PSJ, Whitehead R. Mitosis counting: a need for reappraisal. Hum. Pathol. 1981: 12; 3-4.
18. Sadler DW, Coghill SB. Histopathologists, malignancies, and undefined high power fields. Lancet 1989: 1; 785-786.
19. Donhuijsen K. Mitosis Counts: Reproducibility and significance in grading of malignancy. Hum. Pathol. 1986: 17; 1122-1125.
20. Tsushima K, Rainwater LM, Goellner JR, vanHeerden JA, Lieber MM. Leiomyosarcomas and benign smooth muscle tumours of the stomach: Nuclear DNA patterns studied by flow cytometry. Mayo. Clin. Proc. 1987: 62; 275-280.
21. Yu CC-W, Fletcher CDM, Newman PL, Goodlad JR, Burton JC, Levison DA. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer regions (AgNOR) staining, and histological grading in gastrointestinal stromal tumours. J. Pathol. 1992: 166; 147-152.
22. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumours. Am. J. Surg. Pathol. 1993: 17; 588-594.
23. Cooper PN, Quirke P, Hardy GJ, Dixon MF. A flow cytometric, clinical and histological study of stromal neoplasms of the gastrointestinal tract. Am. J. Surg. Pathol. 1992: 16; 163-170.
24. Dougherty MJ, Compton C, Talbert M, Wood WC. Sarcomas of the gastrointestinal tract. Separation into favourable and unfavourable prognostic groups by mitotic count. Ann. Surg. 1991: 214; 569-574.
25. Oliver GF, Reiman HM, Gonchoroff NJ, Muller SA, Umbert IJ. Cutaneous and subcutaneous leiomyosarcoma: a clinicopathological review of 14 cases with reference to antidesmin staining and nuclear DNA patterns studied by flow cytometry. Br. J. Dermatol. 1991: 124; 252-527.
26. Tsushima K, Stanhope CR, Gaffey TA, Lieber MM. Uterine leiomyosarcomas and benign smooth muscle tumours: usefulness of nuclear DNA patterns studied by flow cytometry. Mayo. Clin. Proc. 1988: 63; 248-255.
27. Schofield JB, Mansi J, Camplejohn S, Lane DP, Fisher C. Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma. J. Clin. Pathol. 1992: 45; 664-667.
28. Boquist LLV. Nucleolar organizer regions in uterine sarcomas. Virchows Arch. (A) Pathol. Anat. 1992: 420; 353-358.
29. Quinn CM, Wright NA. The value of mitotic counting in the assessment of prognosis and proliferation in human tumours. J. Pathol. 1991: 163; 362-363.
30. Weidner N, Moore DH, Vartanian R. Correlation of Ki67 antigen expression with mitotic figure index and tumour grade in breast carcinomas using the novel paraffin reactive K167 antibody. Hum. Pathol. 1994: 25; 337-342.